Several focus issues of conversion therapies for intermediate-advanced hepatocellular carcinoma

doi:10.3969/j.issn.1009-976X.2022.02.001

Abstract

Abstract: Most patients with hepatocellular carcinoma are diagnosed at intermediate-advanced stage in China, losing the chance of long-term survival through surgical resection. In recent years, locoregional therapy and systemic therapies of hepatocellular carcinoma have achieved great progress and more patients with intermediate-advanced unresectable hepatocellular carcinoma are expected to benefit from conversion therapies. After preliminary exploration, the multi-mode and high-intensity conversion therapies through combining locoregional therapy and system therapy has shown a gratifying success rate. However, there is still no consensus on the target population, regimen options and operation opportunity of conversion therapies. The paper reviews the domestic and foreign research progress and discusses several focus issues of conversion therapies for intermediate-advanced hepatocellular carcinoma.

Key words: hepatocellular carcinoma, conversion therapies, downstaging therapies, surgical resection

摘要： 我国大部分肝癌患者初诊时已处于中晚期,失去了通过手术切除获得长期生存的机会。当前系统治疗的发展、局部治疗技术的进步有望让更多中晚期不可切除肝癌患者从转化治疗中获益。经过初步探索,局部联合系统治疗的多模式、高强度的转化治疗方案展现了可喜的转化成功率。然而,关于如何选择转化治疗目标人群及转化方案、何时序贯手术切除在内的一系列问题尚存在争议。笔者回顾国内外相关研究进展,围绕转化治疗中的几个焦点问题进行探讨。

关键词: 肝细胞癌, 转化治疗, 降期治疗, 手术切除

CLC Number:

R735.9

LONG Yin, SONG Xing-dong, ZHANG Lei. Several focus issues of conversion therapies for intermediate-advanced hepatocellular carcinoma[J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 115-119.

龙吟, 宋兴东, 张磊. 中晚期肝癌转化治疗中的几个焦点问题[J]. 岭南现代临床外科, 2022, 22(02): 115-119.

References

[1] Park JW, Chen M, Colombo M, et al.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9): 2155-2166.
[2] Lau WY, Lai EC.Salvage surgery following downstaging of unresectable hepatocellular carcinoma--a strategy to increase resectability[J]. Ann Surg Oncol, 2007, 14(12): 3301-3309.
[3] Chen X, Lai L, Ye J, et al.Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis[J]. Front Oncol, 2021, 11: 740762.
[4] 丁陈陈, 宋兴东, 张磊. 肝脏外科医生眼中的2021 ASCO[J]. 岭南现代临床外科, 2021, 21(3): 265-271.
[5] Zhao HT, Cai J Q.Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma[J]. World J Gastroenterol, 2021, 27(47): 8069-8080.
[6] 曹俊宁, 张雯雯, 赵海涛, 等. 基于免疫联合靶向方案的晚期肝细胞癌转化治疗中国专家共识(2021版)[J]. 肝癌电子杂志, 2021, 8(2): 6-15.
[7] 孙惠川, 谢青, 荚卫东, 等. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6): 618-632.
[8] 肖治宇, 陈亚进. 不可切除中晚期肝癌的转化治疗后肝切除术[J]. 中国实用外科杂志, 2021, 41(3): 275-280.
[9] 赵明,伍家鸣,商昌珍.肝癌转化治疗相关技术方法及评价[J]. 中国实用外科杂志, 2021, 41(3): 262-268.
[10] Yang X, Xu H, Zuo B, et al.Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy[J]. Hepatobiliary Surg Nutr, 2021, 10(4): 434-442.
[11] Llovet JM, Real MI, Montaña X, et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial[J]. Lancet, 2002, 359(9319): 1734-1739.
[12] Zhang Y, Huang G, Wang Y, et al.Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience[J]. Oncologist, 2016, 21(12): 1442-1449.
[13] Parikh ND, Waljee AK, Singal AG.Downstaging hepatocellular carcinoma: A systematic review and pooled analysis[J]. Liver Transpl, 2015, 21(9): 1142-1152.
[14] Li QJ, He MK, Chen HW, et al.Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial[J]. J Clin Oncol, 2022, 40(2): 150-160.
[15] Llovet JM, Ricci S, Mazzaferro V, et al.Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
[16] Kudo M, Finn RS, Qin S, et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
[17] Abou-Alfa GK, Meyer T, Cheng A-L, et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63.
[18] Finn RS, Qin S, Ikeda M, et al.Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
[19] Finn RS, Ikeda M, Zhu AX, et al.Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970.
[20] Gnoni A, Santini D, Scartozzi M, et al.Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?[J]. Expert Opin Ther Targets, 2015, 19(12): 1623-1635.
[21] Zhang J, Zhang X, Mu H, et al.Surgical Conversion for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Using a Triple Combination of Angiogenesis Inhibitors, Anti-PD-1 Antibodies, and Hepatic Arterial Infusion Chemotherapy: A Retrospective Study[J]. Front Oncol, 2021, 11: 729764.
[22] Groot Koerkamp B, Sadot E, Kemeny N E, et al.Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis[J]. J Clin Oncol, 2017, 35(17): 1938-1944.
[23] Gholami S, Kemeny NE, Boucher TM, et al.Adjuvant hepatic artery infusion chemotherapy is associated with improved survival regardless of kras mutation status in patients with resected colorectal liver metastases: a retrospective analysis of 674 patients[J]. Ann Surg, 2020, 272(2): 352-356.
[24] Nonami T, Isshiki K, Katoh H, et al.The potential role of postoperative hepatic artery chemotherapy in patients with high-risk hepatomas[J]. Ann Surg, 1991, 213(3): 222-226.
[25] 陈亚进.肝癌转化治疗现状与思考[J]. 中国实用外科杂志, 2021, 41(3): 253-256+261.
[26] 闫鸣, 程石, 冯国勋, 等. 结直肠癌肝转移的转化治疗[J]. 中国临床医生杂志, 2019, 47(8): 892-895.
[27] He MK, Liang RB, Zhao Y, et al.Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720.
[28] Shi XJ, Jin X, Wang MQ, et al.Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization[J]. Chin Med J, 2012, 125(2): 197-202.
[29] Allard MA, Sebagh M, Ruiz A, et al.Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J]. J Hepatol, 2015, 63(1): 83-92.
[30] Zhang W, Hu B, Han J, et al.Surgery After Conversion Therapy With PD-1 Inhibitors Plus Tyrosine Kinase Inhibitors Are Effective and Safe for Advanced Hepatocellular Carcinoma: A Pilot Study of Ten Patients[J]. Front Oncol, 2021, 11: 747950.
[31] 孙惠川. 不可切除和中晚期肝癌的转化切除[J]. 腹部外科, 2021, 34(2): 85-87.
[32] 夏晓露, 肖玉玲, 邱培, 等. 肝癌根治性切除术后复发的高危因素分析[J]. 实用癌症杂志, 2020, 35(11): 1875-1878.
[33] 黄金球, 彭民浩, 邹全庆, 等. 原发性肝癌切除术后早期复发高危因素分析[J]. 中国实用外科杂志, 2009, 29(5): 418-420.
[34] 李豪, 陈国勇, 魏思东, 等. 原发性肝癌患者肝切除术后复发影响因素分析[J]. 中国肝脏病杂志(电子版), 2019, 11(3): 69-74.
[35] Zhou H, Song T.Conversion therapy and maintenance therapy for primary hepatocellular carcinoma[J]. Biosci Trends, 2021, 15(3): 155-160.
[36] Nouso K, Miyahara K, Uchida D, et al.Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan[J]. Br J Cancer, 2013, 109(7): 1904-1907.
[37] 宋天强, 刘雅月. 原发性肝癌转化治疗及其维持治疗策略[J]. 中国实用外科杂志, 2021, 41(3): 269-272.